Chronic Myelogenous Leukemia

“More than 600 patients are benefited through this program”

AMANC  ”Sólo por Ayudar” has signed an agreement with Novartis Pharmaceutical Laboratories in order to receive the medicine to treat patients who suffer this illness with extraordinary results.

Mexico is working in activities to promote and allow diagnose and early detection of chronic myelogenous leukaemia. Our goal is to raise more funds in order to treat more people who need our help.

“Today more than 600 people without any social security insurance are being supported through this program “.

Share This